This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Legal and regulatory update
Go to paperABSTRACT: Article 81(1) of the Treaty of Rome prohibits all agreements, decisions and concerted practices that ma…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Growth of Indian biotech companies, in the context of the international biotechnology industry
Go to paperABSTRACT: The paper discusses the evolution and…

TechTransferWatch is a search engine and alert service for licenseable technologies from academic labs, foundations, and government. Click the patents

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
Patent issues and future trends in drug development
Go to paperABSTRACT: The global biopharmaceutical industry has been one of the most productive and p…

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology
ApaTech: A biomaterials success story
Go to paperABSTRACT: ApaTech is an excellent example of how innovative technology from a British university can be…

This paper is part of the free Open Access archive of the Journal of Commercial Biotechnology

Why data exclusivity is the new patent protection

Go to paper

ABSTRACT:   

The Journal of Commercial Biotechnology is a unique forum for all those involved in biotechnology commercialization to present, share, and explore new ideas, latest thinking and best practices, making it an indispensable guide for those developing projects and careers within this fast moving field.

Each issue publishes peer-reviewed, authoritative, cutting-edge articles written by the leading practitioners and researchers in the field, addressing topics such as:

• Management
• Policy
• Finance
• Law
• Regulation
• Bioethics

For more information, see the Journal of Commercial Biotechnology website

Brazil is looking into foreign technology to foster innovation in the country’s industrial health complex. Biological plants are being built and partnerships with multinationals have been established with the goal to in license technology, manufacture and supply the population with biosimilars made in Brazil. This article brings up-to-date information on the biosimilar market in the country, with information on the public-private partnerships and regulatory approvals. With two biosimilars approved in 2015 and the ongoing development regarding the local pharmaceutical companies, there is a good window of opportunity to create new businesses in the soon to be 4^th pharmaceutical spender in the world. 

As the global life sciences industry changes, the most successful regions in attracting inward investment will be those that evolve and adapt to provide the most attractive offer. In Scotland, the government is developing an environment to “push” its life sciences sector to complement the strong “pull” that these changes in the global life sciences industry and in investor sentiment have created.

The Scottish Government and the life sciences industry have developed a strategy that aims to anchor in Scotland those businesses that provide vital skills and market access; increase the number of more resilient companies and comprehensive supply chains; and attract new inward investment and talent that will build on Scotland’s existing capabilities.

The Scottish Government is improving on the country’s existing strengths and aims to capitalise on prior investment in Scotland’s research excellence, particularly in areas such as stem cells and regenerative medicine and ”precision medicine”, where there are significant current and emerging commercial opportunities.